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Abstract Tehranolide, natural sesquiterpene lactone with an
endoperoxide group, has been shown to inhibit cell growth in
cancer cells. Tehranolide was purified from Artemisia diffusa .
To detect cell viability and proliferation, MTT assay was
performed. In order to determine the role of tehranolide on
calmodulin (CaM) structure and activity, its effects were eval-
uated with fluorescence emission spectra and CaM-mediated
activation of phosphodiesterase (PDE1), in comparison with
artemisinin. In fact, PDE1 inhibition, cAMP accumulation,
and cAMP-dependent protein kinase A (PKA) activation were
examined. The inhibitory effect of tehranolide on CaM struc-
ture is more than artemisinin. The kinetic analysis of
tehranolide–CaM interaction has shown that this agent com-
petitively inhibited the activation of PDE1 without affecting
Vmax. Tehranolide increased Km value in higher amounts
compared with artemisinin. Moreover, tehranolide had a cy-
totoxic effect on K562 cell line but not on normal human
lymphocytes. Additionally, PDE inhibition and consequent
cAMP accumulation and PKA activity were required for
inhibiting cancer cell growth by tehranolide. Our results show
that tehranolide significantly reduces cell proliferation in a
time and dose-dependent manner in K562 cells via CaM
inhibition, following PDE inhibition, cAMP accumulation,
and consequent PKA activity.






PKA cAMP-dependent protein kinase A
Introduction
Cell proliferation is regulated by a complex array of signaling
pathways. cAMP acts as an important second messenger in
many pathways regulating cell growth, differentiation, and
apoptosis [1]. The elevation of cAMP subsequently activates
cAMP-dependent PKA that can phosphorylate various pro-
teins, thus regulating a cascade of transcriptional events im-
plicated in the inhibition of cancer cell growth [2–4]. PDEs
degrade cAMP and promote the return of PKA to its inactive
tetrameric state [5]. PDE is an isozymic family composed of
many different types, grouped into seven broad gene families
including Ca2+CaM-dependent (PDE1) [6].
PDE inhibitor-induced apoptosis is selective towards ma-
lignant cells without affecting normal cells [7]. CaM has been
shown to play roles in regulating apoptosis [8]. CaM antago-
nists induce apoptosis in various tumor models. Thus, CaM is
involved in the regulation of biological processes such as cell
proliferation [9] and has been extensively used as anticancer
agents, but the molecular mechanism of CaM antagonist-
mediated apoptosis is poorly understood [3, 10].
Artemisinin (Fig. 1), a natural sesquiterpene lactone with
an endoperoxide group, has been extracted from Artemisia
annua . Artemisinin has effective antitumor activities [11–15].
Tehranolide (Fig. 1) is classified as sesquiterpene lactone with
an endoperoxide group which is purified from Artemisia
diffusa [16]. It was previously demonstrated that artemisinin
and DHA have inhibitory effects on CaM and PDE1 activity
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[17–19]. It was reported that tehranolide possessed antitumor
activities, and it arrested cells in the G1 phase [20–22]. In the
present study, the effects of tehranolide on CaM, PDE1, and
the cAMP/PKA signaling pathway to define the mechanism
of cell growth inhibition were investigated.
Materials and methods
Isolation and purification of tehranolide
One thousand grams of A . diffusa were collected from East of
Iran. Dry plant was extracted by a mixture of n-hexane/ethyl
acetate/methanol (1:1:1) and kept in room temperature for
24 h. The extract was passed through Wattman filter paper.
The filtrate was evaporated by vacuum rotary evaporator at
45 °C for 2 h and kept in freezer. The concentrated filtrate was
run through a silica gel column chromatography at different
solvent polarities starting from a nonpolar solvent (n-hexane)
to a medium polarity (n-hexane/ethyl acetate) and ended with
ethyl acetate alone. Then, mixtures of different concentrations
of n-hexane/ethyl acetate/methanol with increasing concentra-
tion of methanol towards the higher polarity were used.
Fractions were collected from these processes, and the purity
of the components in each fraction was evaluated by thin layer
chromatography (TLC). Fractions 35, 36, 37, 38, 39, 40, 41,
and 42 exhibited a single band on TLC. Afterwards,
tehranolide was identified by the 125 MHz 13C NMR spectra,
using CDCl3 as a solvent.
Spectrofluorophotometer
Fluorometric measurements were carried out using a
Shimadzu Model RF-5000 spectrofluorometer. The instru-
ment was operated in the energy mode, and the emission
spectrum of CaM was studied at λex=277 nm and λem=
310 nm. Tehranolide and artemisinin had no fluorescence
activity at these wavelengths.
Assay for PDE-1 activity
A modification of a three-step PDE1 assay was used to deter-
mine CaM-dependent activation of PDE1 and its inhibition by
tehranolide. 3,5–cyclic–nucleotide PDE, 2-mM cyclic AMP,
and 100 μM CaM in 0.5 ml of Tris buffer solution (40 mM





Fig. 1 a Chemical structures of
artemisinin and tehranolide. b
13C NMR spectroscopy of
tehranolide
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of distilled water at pH 7.5) were incubated alone, with
increasing concentrations of native tehranolide (1×10−6 to
9×10−6 M) for 10 min at 30 °C. The reaction was stopped
by placing the test tubes in a boiling water bath for 2 min and
then cooling. The 5-AMP in the reaction product was cleaved
into adenosine and inorganic phosphate by incubation with 5'-
nucleotidase (100 μl) for 10 min. The reaction was stopped by
adding 0.05 ml of trichloride acid (55 %, weight to volume)
and 0.15mlmolybdic acid solution and centrifuged until clear.
The clear supernatants were decanted into the test tubes with
Fiske-Subbarow reagent. Blue color reaction was allowed to
develop in the presence of inorganic phosphorus for 10 min.
Absorbance at 660 nmwasmeasured with spectrophotometry.
Determination of the kinetic parameters
ΔG (H2O), the best parameter for the estimation of macromol-
ecule stability, was determined for CaM in the presence of
tehranolide and artemisinin. The difference between the free
energy of the native and denatured forms of CaM (ΔG) was
calculated using [23] the following equation:
Δ G ¼ − RT Ln Fd= 1−Fdð Þ½ 
Fd ¼ Yn−Yobsð Þ= Yn−Ydð Þ
Ln Yn−Yobsð Þ= Yobs−Ydð Þ½  ¼ −RTLnK
ð1Þ
Where R is the gas constant, T is the absolute temperature,
Yobs is the observed fluorescence emission intensity of CaM at
each concentration of artemisinin, and tehranolide Yn and Yd
are the values for the native and denatured states, respectively.
The plot of ΔG changes against tehranolide and artemisinin
concentrations showed a linear behavior with the following
equation [23]:
ΔG ¼ ΔG H2Oð Þ−m D½  ð2Þ
Where ΔG (H2O) is the value of ΔG at zero concentration
of ligand, m is a measure for the dependence of ΔG on ligand
concentration, and [D] is the concentration of ligand.
A kinetic analysis of the inhibition of CaM-dependent PDE
by tehranolide and artemisinin resulted in Lineweaver–Burk
plots. Km values were calculated in the absence and presence
of inhibitors fromLineweaver–Burk plots of data. The point at
which the lines crossed the y -axis represents the theoretical
maximum velocity (Vmax) of the activated PDE1 in the
presence and absence of inhibitors.
Cell culture
The human erythroleukemic cell line (K562) was purchased
from Pasteur Institute, Tehran, Iran. In this study, the cells were
cultured in RPMI 1640 medium (Gibco/BRL) supplemented
with 10% FBS (GIBCO/BRL), 100 unit/ml penicillin/100mg/
ml streptomycin, and 1% L-glutamine (Gibco/BRL). The cells
were grown in a humidified atmosphere containing 5%CO2 at
37 °C. Normal lymphocytes were collected from healthy per-
sons. Human peripheral blood was obtained from healthy
volunteers (aged 25–50 years). Blood samples were obtained
by venipuncture of the vein, and blood was collected in sterile
EDTA K3-containing tubes.
PBMCs were obtained by centrifugation over 1.077 g/ml
Ficoll–Hypaque gradient (Sigma, UK).
Cells were washed in saline and finally resuspended in
RPMI 1640 medium and cultured (5×104 cells/ml) in 96-
well flat-bottom culture plates in medium supplemented with
different doses of tehranolide, 10 % fetal calf serum, 2 mm L-
glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin
(Sigma-Aldrich), and the cell viability analysis was measured.
Cell viability analysis
Analysis of cell viability was performed with MTT (3-[4, 5-
methylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide) assay.
Briefly, growing cells were cultured (5,000 cells/well) over-
night in 96-well tissue culture plates. Different doses of
tehranolide were added to the respective wells, after 24, 48,
and 72 h, 20 μL MTT (Sigma-Aldrich, USA) was directly
added to the media with a final concentration of 2 mg/ml.
After 4-h incubation, the medium containing MTT was
discarded, and 100 μL DMSO (Sigma-Aldrich, USA) was
added. MTT crystals were completely solubilized with libra-
tion for 10 min. Absorbance was measured in an ELISA
reader at 570 nm, and viability was expressed as the percent-
age of untreated controls.
Quantitative determination of cAMP concentration
The intracellular cAMP content was determined using cAMP
enzyme immunoassay kit (Stratagene, La Jolla, CA). Briefly, a
total of 2×105 cells were washed with phosphate-buffered
saline (PBS) and harvested with centrifugation. Cell pellets
were resuspended in lysis reagent provided by the kit. The
lysed cells were immediately assayed for cAMP according to
the manufacturer's protocol. The assay was based on compe-
tition between unlabeled cAMP and a fixed quantity of
peroxidase-labeled cAMP for a limited number of binding
sites on a cAMP-specific antibody.
Measurement of PKA activity
PKA activity was measured using the colorimetric PKA assay
kit. The treated cells were washed with ice-cold PBS twice,
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resuspended in lysis buffer (50 mMTris–HCl, 2.5 mMEDTA,
1 mMMgCl2, 10mMNaF, 10% glycerol, pH 7.2), sonicated,
and centrifuged. Supernatants were taken as lysates. Thirty
micrograms of cell lysate was used to measure PKA activity.
PKA activity assays were performed following the manufac-
turer's instructions included with the colorimetric PKA assay
kit.
Blocking PKA activation on cell growth inhibition
Rp-cAMP (Adenosine 3,5-cyclic monophosphorothioate
triethyammonium salt hydrate), a specific inhibitor of
cAMP-dependent protein kinase A (Biolog Life Science In-
stitute, Bremen, Germany), was purchased from Sigma and
diluted in supplemented RPMI to the required concentra-
tions. Cells were preincubated with Rp-cAMP for 20 min
before treatment with tehranolide.
Statistical analysis
At first, normality of the data and homogeneity of variances
were tested with K–S and Levene's statistical tests, respectively.
Then, one-way analysis of variance or Mann–Whitney non-
parametric test was used to determine the statistical significance
(p <0.05) between values of test and control groups. Data were
analyzed using SPSS software version 16, and results were
expressed as the mean ± standard error (mean ± SE).
Results
Tehranolide structure
The purified material was characterized by 13C NMR spec-
troscopy. The structure of tehranolide has been shown in
Fig. 1.
Interaction of tehranolide with calmodulin
The inhibitory effect of the drug on CaM structure was deter-
mined by fluorescence emission spectra; the change of fluo-
rescence emission spectra of CaM indicated the interaction of
ligand with CaM, representing the drug-induced conforma-
tional changes of CaM. These results were shown an increase
in maximum emission of CaM, which was induced by both
tehranolide and artemisinin (Fig. 2a).
Inhibition of CaM-dependent cAMP PDE-1 by tehranolide
An increased concentration of tehranolide was tested based on
the measurement of enzyme activity. Themethod involved the
hydrolysis of cAMP to AMP that was quantified with the
spectrophotometer method. PDE1 activity was plotted against
the concentrations of tehranolide (Fig. 2b).
Kinetic analysis of PDE1 activity and inhibition of PDE1
by tehranolide
The kinetic constant of PDE1was determined. Km value
of PDE1 in the absence of inhibitor was 0.05±0.001 μM;
whereas in the presence of tehranolide and artemisinin, it
was 0.1 and 0.5 μM, respectively, suggesting that in the
presence of tehranolide and artemisinin, the Km values
increased in a concentration-dependent manner. The results
indicated that tehranolide and artemisinin increased the
Km value without affecting Vmax of the reaction. The
Lineweaver–Burk plots demonstrated that both agents were
competitive inhibitors of PDE1 (Fig. 3a). The effectiveness of
the inhibitors is normally expressed by the constant, Ki, which
is the reciprocal of the enzyme-inhibitor affinity. In addition,
Ki values were determined using a Dixon plot (Fig. 3b). The
Fig. 2 a The fluorescence spectra of calmodulin at 0.043 mg/ml con-
centration in 40 mM Tris–HCl buffer, pH 7.4 at 25 °C. The increment in
the fluorescence emission of calmodulin by increasing its concentration in
the free form and in the presence of 10−5 M of artemisinin or 10−5 M of
tehranolide. b Calmodulin-dependent PDE1 activity versus the concen-
trations of artemisinin and tehranolide
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Ki constants for tehranolide and artemisinin were 6.1 and
10 μM, respectively.
The effect of tehranolide on calmodulin stability
The procedure was performed for CaM in the presence of
tehranolide and artemisinin, separately. The ΔG changes for
the complexes of CaM with tehranolide and artemisinin were
shown in Fig. 4. The estimated ΔG (H2O) from the linear
curves in the presence of tehranolide was 2.13 kcal mol−1,
while this value was 4.16 k cal mol−1 in the presence of
artemisinin (Table 1).
Measurement of cell growth
To measure the effect of tehranolide on growth of tumor cells,
different doses of tehranolide were tested; the results indicated
that tehranolide reduced the growth of K562 cell line in a
concentration-dependent manner.
MTT assay indicated that tehranolide had no cytotoxic
effects on the growth of peripheral blood lymphocytes, but it
was effective in growth inhibition of K562 cell line (Fig. 5a).
The effect of tehranolide on intracellular levels of cAMP
and PKA activity in K562 cells
To determine the level of cAMP accumulation and PKA
activity in the K562 cells in response to tehranolide, cAMP
content and PKA activity were measured using enzyme im-
munoassay. In response to tehranolide and artemisinin (PDE1
inhibitors), intracellular cAMP accumulation were observed
in K562 cells (Fig. 5b, c). Additionally, tehranolide-treated
group showed a significant increase in PKA activity compar-
ing with control group (Fig. 5d).
Activation of PKA by cAMP is required
for tehranolide-induced cell growth inhibition
To confirm that the effect of tehranolide on cell growth inhi-
bition was mediated by PDE inhibition and the consequent
increase of cAMP and PKA activation, cells were preincubated
for 20min with specific inhibitor of PKA (Rp-cAMP) (10 μM)
and then treated with tehranolide (35–75 μM); afterwards,
MTT assay was performed.
Fig. 3 a Kinetic analysis of the PDE1 activity and themode of inhibitory
action of both compoundswas examined using the Lineweaver–Burk plot
method. Inhibition was performed with 5 μM tehranolide and 5 μM
artemisinin in varying concentrations of cAMP (calmodulin concentra-
tion in all the reactions was constant, 100 μM). b Dixon plots: Inhibition
was performed with varying concentrations of artemisinin and
tehranolide
Fig. 4 The changes of free energy (ΔG) versus the varying concentra-
tions of tehranolide and artemisinin (μM)











Calmodulin 5 6.7 0.1611 39.66 0.99
Artemisinin 5 4.16 0.1179 36.81 0.99
Tehranolide 5 2.13 0.088 30.34 0.99
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Discussion
CaM, a Ca2+-dependent regulatory protein, has been shown to
overexpress in malignant and transformed cells [24, 25],
resulting in alterations in the interaction of CaM with its target
proteins [3]. Furthermore, CaM antagonists have been shown
to inhibit tumor cell invasion in vitro [26]. Moreover, PDE
inhibitors induce apoptosis in malignant cells, without affecting
Fig. 5 a Cytotoxicity effect of tehranolide against of K562 cell line.
Cells were incubated with increasing concentrations (35–75 μM) of
tehranolide for 24, 48, and 72 h Cell viability was quantified by applying
the MTT assay. Bars represent the mean ± SEM of three independent
experiments performed in triplicate, p<0.05 represents significant differ-
ences compared to control values, whereby control was set as 100 %. b
Intracellular levels of cAMP in tehranolide-treated K562 cells. K562 cells
were treated with varying concentrations of tehranolide followed by
analysis of intracellular cAMP levels. c Intracellular levels of cAMP in
artemisinin-treated K562 cells. d PKA activity in tehranolide-treated
K562 cells. PKA activity was determined using the Pierce colorimetric
assay kit that utilizes a fluorescent-labeled kempeptide (a PKA-specific
peptide (LRRASLG) substrate). e RpcAMP, a specific inhibitor of
cAMP-dependent protein kinase A, inhibits PKA activation induced by
cAMP. To detect the role of PKA activity on cell proliferation, cells were
pretreated with RpcAMP(10 μM) for 20 min and then treated with
different concentrations of tehranolide and harvested at 24, 48, and
72 h. Significant differences (p <0.05) were found compared with
untreated cells. The results are representative of three separate
experiments
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normal cells [27]. PDE inhibitors are also currently available or
in development for treatment of a variety of other pathological
conditions. In the recent years, it has been shown that
artemisinin and its derivatives have anticancer effects [28–30].
According to the previous results, our team follows up the
research in two steps: In the first step, tehranolide was purified
from A . diffusa , its effect on CaM structure was investigated
by spectrofluorometry. Our findings indicated that tehranolide
induced some conformational changes on the CaM and in-
creased fluorescence emission of CaM; the inhibitory effect of
tehranolide was higher than artemisinin, as shown in Fig. 2a.
Subsequently, the effects of CaM activation on PDE1 in the
absence (control) and presence of artemisinin or tehranolide
were studied, and the kinetic analysis of PDE1 activity was
performed. It was demonstrated that tehranolide is a more potent
inhibitor of PDE1 activity than artemisinin (Fig. 2b). The plot of
CaM-dependent PDE activity versus tehranolide and artemisinin
concentrations (Fig. 2b) demonstrated that tehranolide and
artemisinin could both inhibit the CaM-dependent activity of
PDE1.However, tehranolide actedmore potent than artemisinin.
It was found that tehranolide has a higher Ki constant (6.1 μM)
compared with artemisinin (10 μM), as shown in Fig. 3a.
On the other hand, tehranolide and artemisinin could act
synergistically and increase the Km value of PDE1, while
Vmax was constant in the presence or absence of both com-
pounds. The data confirmed that these agents competitively
inhibited the activation of PDE1 without affecting Vmax. This
parameter was used to estimate CaM stability after the com-
plex formation with artemisinin or tehranolide.
As shown in Fig. 4, the calculated ΔG (H2O) values are in
agreement with our abovementioned findings. The decrease in
ΔG (H2O) value is the main reason for the decrease in protein
stability because of its interaction with the mentioned ligands.
However, the level of decrease in ΔG (H2O) value appeared to
be in the order of tehranolide > artemisinin, and this means
that tehranolide induces more instability in CaM structure,
indicated by lower ΔG (H2O).
In addition, the concentration required for tehranolide to
interact with CaM is lower than artemisinin, suggesting that
tehranolide has higher affinity for interaction with CaM,
which is related to its structure. This interpretation has been
confirmed with the higher m-value which is a measure of
protein sensitivity to ligand [21], and the lower D1/2, which
is the ligand concentration that induces instability in half of
the protein molecules (Table. 1).
In the second step, the cytotoxic activity of tehranolide was
investigated. It was found that tehranolide inhibited growth of
K562 cells, while it had no cytotoxic effect on the growth of
peripheral blood lymphocytes, as shown in Fig. 5a. In an
attempt to elucidate the role of raised levels of cAMP and
PKA activity in cell growth inhibition by tehranolide and
artemisinin, the intracellular cAMP content by enzyme immu-
noassay were measured, as shown in Fig. 5b, c.
It is hypothesized that cell growth inhibition by tehranolide
is via a PKA-mediated mechanism.
To test this hypothesis, the effect of tehranolide on
PKA activity was evaluated. Our results have shown
that tehranolide leads to increased activity of PKA, as
shown in Fig. 5d.
Finally, to address whether PKA plays a role in the cyto-
toxic activity of tehranolide, cells have been pretreated with
a specific PKA inhibitor (Rp-cAMP) in the presence of
different concentration of tehranolide and the cytotoxicity
indicated by MTT assay, as shown in Fig. 5e. As a conclu-
sion, treatment of cells with tehranolide in the presence of
pRp-cAMP strongly decreases the inhibitory effects of
tehranolide in K562 cells.
Through this study and based upon our pervious results, it
was confirmed that tehranolide, as a potent CaM antagonist,
causes an increase in the cAMP concentration following
PDE1 inhibition. Tehranolide significantly reduces cell prolif-
eration in a time and dose-dependent manner in K562 cells
which probably involves modulating cAMP/PKA signaling
pathways via CaM and PDE inhibition. Thus, in short,
tehranolide has a great potency as an antitumor agent.
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